MTOR Inhibitors Potentially Preserve Fertility in Female Patients with Haematopoietic Malignancies: a Narrative Review

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Nov 13

PMID 39537993

Authors

Yuji Tanaka

Tsukuru Amano

Akiko Nakamura

Mari Deguchi

Akimasa Takahashi

Shunichiro Tsuji

Takashi Murakami

Affiliations

Soon will be listed here.

Abstract

Haematologic malignancies are considered among the more common adolescent and young adult (AYA) cancers. Many female AYA patients with haematopoietic malignancies face impaired fertility. Haematologic malignancies patients tend to be treated with more aggressive systemic chemotherapy than that of solid tumours. In adult women, treatment-related contraception causes age-related fertility loss. Graft-versus-host disease (GVHD) after allogeneic haematopoietic stem cell transplantation is associated with decreased fertility. Ovarian cryopreservation is often indicated for haematopoietic malignancies; however, follicle loss associated with ovarian cryopreservation and ovarian minimal residual disease, which result in the withdrawal of the transplantation, are important issues. These problems may not be fully addressed by conventional methods of fertility preservation, such as oocyte, embryo, and ovarian cryopreservation, leaving room for research into new treatment approaches, such as fertility preservation drugs. In recent years, preclinical studies have shown that mTOR inhibitors may preserve chemotherapy-induced follicular loss, may have follicle-preserving effects on follicle loss associated with cryopreservation and transplantation of ovarian tissue, may have fertility-preserving effects on aging-related infertility. Clinical studies have shown that mTOR inhibitors may have the potential for indirect fertility preservation by controlling GVHD, have a limited anti-tumor effect against haematopoietic malignancies. The purpose of this article is to outline the various issues faced by female survivors of haematopoietic malignancies and discuss the potential of mTOR inhibitors as a safe treatment option. Based on current research, mTOR inhibitors seem promising and innovative fertility preservation agents regarding preclinical conditions, and further study, including clinical trials, should be expected.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Li D, Zhao Y, Wang Q, Chu M, Xie J, Zhang C . Fertility preservation in hematological cancer patients. Clin Transl Oncol. 2024; 26(8):1836-1843. DOI: 10.1007/s12094-024-03419-2. View

Ozdemir Z, Bozdag S . Hematological Malignancies and Fertility. Adv Exp Med Biol. 2020; 1288:103-115. DOI: 10.1007/5584_2020_490. View

Turan V, Bedoschi G, Rodriguez-Wallberg K, Sonmezer M, Pacheco F, Oktem O . Utility of Gonadotropin-Releasing Hormone Agonists for Fertility Preservation: Lack of Biologic Basis and the Need to Prioritize Proven Methods. J Clin Oncol. 2018; 37(1):84-86. DOI: 10.1200/JCO.18.00420. View

Senra J, Roque M, Talim M, Reis F, Tavares R . Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017; 51(1):77-86. DOI: 10.1002/uog.18934. View

Faivre S, Kroemer G, Raymond E . Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5(8):671-88. DOI: 10.1038/nrd2062. View

Panwar V, Singh A, Bhatt M, Tonk R, Azizov S, Raza A . Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023; 8(1):375. PMC: 10543444. DOI: 10.1038/s41392-023-01608-z. View

Zou Z, Tao T, Li H, Zhu X . mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020; 10:31. PMC: 7063815. DOI: 10.1186/s13578-020-00396-1. View

Popova N, Jucker M . The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int J Mol Sci. 2021; 22(4). PMC: 7916160. DOI: 10.3390/ijms22041743. View

10.

Mao B, Zhang Q, Ma L, Zhao D, Zhao P, Yan P . Overview of Research into mTOR Inhibitors. Molecules. 2022; 27(16). PMC: 9413691. DOI: 10.3390/molecules27165295. View

11.

Harrison D, Strong R, Sharp Z, Nelson J, Astle C, Flurkey K . Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253):392-5. PMC: 2786175. DOI: 10.1038/nature08221. View

12.

Anisimov V, Zabezhinski M, Popovich I, Piskunova T, Semenchenko A, Tyndyk M . Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011; 10(24):4230-6. DOI: 10.4161/cc.10.24.18486. View

13.

Neff F, Flores-Dominguez D, Ryan D, Horsch M, Schroder S, Adler T . Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013; 123(8):3272-91. PMC: 3726163. DOI: 10.1172/JCI67674. View

14.

Miller R, Harrison D, Astle C, Fernandez E, Flurkey K, Han M . Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2013; 13(3):468-77. PMC: 4032600. DOI: 10.1111/acel.12194. View

15.

Waxman D, Holloway M . Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009; 76(2):215-28. PMC: 2713118. DOI: 10.1124/mol.109.056705. View

16.

Strong R, Miller R, Astle C, Floyd R, Flurkey K, Hensley K . Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell. 2008; 7(5):641-50. PMC: 2695675. DOI: 10.1111/j.1474-9726.2008.00414.x. View

17.

Harrison D, Strong R, Allison D, Ames B, Astle C, Atamna H . Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2013; 13(2):273-82. PMC: 3954939. DOI: 10.1111/acel.12170. View

18.

Jagarlamudi K, Liu L, Adhikari D, Reddy P, Idahl A, Ottander U . Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation. PLoS One. 2009; 4(7):e6186. PMC: 2702689. DOI: 10.1371/journal.pone.0006186. View

19.

Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y . Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008; 319(5863):611-3. DOI: 10.1126/science.1152257. View

20.

Fan H, Liu Z, Shimada M, Sterneck E, Johnson P, Hedrick S . MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility. Science. 2009; 324(5929):938-41. PMC: 2847890. DOI: 10.1126/science.1171396. View